PFP.NGO

PARTNERS FOR PATIENTS

SINCE 1990

Partners for Patients NGO (PFP.NGO) in Partnership with
Ghana Department of Defense and the Ghana Armed Forces

Project C.A.R.E Initiative

September 21, 2022 to September 23, 2022

Accra, Ghana

DELEGATION BROCHURE

PFP.NGO's PROJECT C.A.R.E. Initiative BACKGROUND

PROJECT C.A.R.E.: Collaborate to Advance Research Excellence to advance health equality and health equity in Africa and across the world.

PROBLEM BEING ADDRESSED: For many years the industry has lacked the ability to provide access to medical innovations for underserved communities in respect to race, socioeconomic status and other challenges.

PROJECT C.A.R.E. MISSION: To enable established healthcare providers to evolve their practices to become centralized and decentralized investigative sites in their underrepresented communities by providing long term sustainable infrastructures, technologies and services.

PROJECT C.A.R.E. GOAL: Advance clinical trials readiness in 193 countries using industry standards, including education, certifications, patient screening instruments, managerial technologies, global privacy, and General Data Protection Regulation (GDPR) technologies to modernize the clinical trial process in underserved communities.

PARTNERS FOR PATIENTS
SINCE 1990

PROJECT C.A.R.E PILOT PROJECT: GHANA2022

PROJECT C.A.R.E. GHANA GOAL: Ensure health equity and health equality for EVERY patient in Ghana and on the African continent as our core delegation mission.

HEALTH EQUITY: **Every patient has a fair and just opportunity to be healthy.**
HEALTH EQUALITY: **All patients are being treated the same way.**

2022 GHANA DELEGATION GOALS:

1. Operationalize a center of excellence to address health equality and health equity for patients on the African continent.

2. Complete local ICG-GCP/clinical trials education for:
   a. **Patients**
   b. **Family engaged caregivers**
   c. **Key Opinion Leaders (KOLs)**
   d. **Therapeutic Area Experts (TAEs)**
   e. **Healthcare practitioners**
   f. **Nurses**
   g. **Pharmacists**
   h. **Ghana Department of Defense**
   i. **Ghana Armed Forces**
   j. **Ghana FDA**
   k. **Ghana Ministry of Health**

3. Complete a national hospital tour in Ghana to support the pre-screening of potential Ghana clinical trial sites to pre-qualify for a potential proof of concept pilot clinical trial.



GHANA2022 Schedule at a Glance

WELCOME GHANA DELEGATION TEAM — DAY 1

Wednesday, September 21, 2022 at 12 pm UTC - 5 pm UTC

on the GHANA ARMED FORCES MILITARY CAMPUS

ITEM	TOPIC	TIME
1.	**Welcome Local ICH-GCP Training Attendees/ Introductions**	15 min
	BREAKFAST WILL BE SERVED AT 5:45 am UTC	
2.	**Clinical Trials School Agenda Overview:**	15 min

- Kick-Off ICH-GCP training certificate for non-specific protocols rare disease care and cancer care
- Course will cover an overview of BASIC ICH-GCP training lecturer, University Faculty of Medicine, Head of the International Hematology Society

A. Why should clinical research be done? What is clinical trial?
B. Declaration of Helsinki and Good Clinical Practice (GCP) Guidelines
C. Law in clinical trials and law of protection of personal data in clinical studies

NETWORKING BREAK

D. Clinical trial designs, clinical trial phases & methodology
E. Roles and responsibilities in clinical trials
F. Legislation and Regulatory Authority: Ghana Medicines and Medical Devices Agency Clinical Trials Department
G. Ethics committees, members and responsibilities, Dean of Faculty of Pharmacy-Toxicology Department Head
H. Investigator's responsibilities, University, Faculty of Medicine, Department of Oncology

NETWORKING BREAK

I. Informed consent form (ICF) and workshop (how to obtain a right form) University, Faculty of Medicine, Department of Oncology
J. Sponsor and contract research organisation (CRO) responsibilities
K. Statistical concepts and applications in clinical research. University, Cancer Institute Director
L. Safety and workshop in clinical trials (pharmacovigilance, side effect reports) University Vice Dean of Faculty of Pharmacy
M. Research principles and publication ethics President of the International Society of Hematology

LUNCH BREAK
CLOSE ICH-GCP TRAINING

SEPTEMBER 21, 2022

OPTIONAL RECEPTION DINNER

IN ACCRA AT 7 PM UTC- LOCATION TBC BY THE GHANA DEPARTMENT OF DEFENCE

GHANA2022 Schedule at a Glance

WELCOME GHANA DELEGATION TEAM — DAY 2

Thursday, September 22, 2022 at 12 pm UTC - 5 pm UTC

on the GHANA ARMED FORCES MILITARY CAMPUS

ITEM	TOPIC	TIME
1.	**Welcome Delegation Team/ Introductions**	45 min
	BREAKFAST WILL BE SERVED AT 6:45 am UTC	
2.	As a part PFP.NGO's diversity and inclusion strategy, in collaboration with The Department of Defence, Ghana Ministry of Health, Ghana FDA, Ghana Armed Forces, Ghana Myeloma Health Practitioners, Ghana Haematologist, and Ghana Patients and Care Partners, PFP.NGOs delegation aims to expand access options by conducting a proof-of-concept potential clinical trial. Potential Clinical Trial Proof of Concept (POC) to Explore: Our potential POC clinical trial will be evaluated during the Ghana National Hospital Tours.	
	LUNCH NETWORKING BREAK TRANSITION TO DELEGATION HOSPITAL TOURS	
	(On Tour: Visiting Ghana Hospitals across Ghana to potentially pre-screen and pre-qualify sites for potential clinical trial pilot).	
3.	**Update on the implementation of the Governance** **GOAL:** • Pre-screen potential sites to pre-qualify for potential upcoming clinical trial sites • To address the unmet medical care for patients in Africa through operationalizing a Centre of Excellence for clinical trials • Complete local ICH-GCP training	60 min
4.	**Discussion on Clinical Trial Quality (CTQ)** **(On Tour: Visiting Ghana Hospitals)** Defining clinical trial quality from the perspective of resource-limited settings. **Site Audits** Audit of the documentation and procedures performed at the clinical site. This assures the sponsor that the clinical site is adhering to the study protocol and all applicable regulations. **Trial Master File (TMF) Audits** Audit of the documentation contained in the TMF, ensuring that the TMF is always ready for an regulatory inspection and that it adheres to the project plan and GCP.	60 min

(continued next page)

WELCOME GHANA DELEGATION TEAM **DAY 2** continued

ITEM	TOPIC	TIME

NETWORKING BREAK

Vendor Audits
Prequalification or maintenance audit of documentation and services provided by a vendor, verifying that either the vendors have the processes and procedures in place to be able to perform the services needed for the study (prequalification); and/or the vendor is performing the services per the study protocol and applicable regulations throughout the contract period (maintenance).

Computer Validation Audits
Audit of all documentation that is generated during the validation of a computer system, making sure the system is compliant with all applicable regulations.

Database Audits
Audit of the documentation associated with a database lock, ensuring that the proper procedures have been performed prior to locking the data at the end of a study.

Internal Process Audits
Focuses on ensuring that each department is paying attention to quality standards of their job.

Routine Training File Audits
Perform annual routine training file audits of all employees; hence, this process ensures that the training documentation uploaded to the TMF is up-to-date (demonstrating that the personnel working on their study are qualified to do so).

NETWORKING BREAK

Mini-Process Audits
These audits capture manageable sections of the study, which allows the team to proactively solve issues rather than scrambling at the end. The value to sponsors is that these audits save both time and expense and ensure that every part of the study process is performed correctly.

Training
Ongoing training means better oversight for audits/inspections. The QA team is the administrator of all training, which allows for better oversight during an audit/inspection. Training ensures that the personnel working on studies are properly qualified and prepared.

Quality Gap Analysis
Gap analysis helps to identify areas where processes/procedures may be lacking or not strong enough to meet quality standards. Assess and assist to identify where there are gaps before an audit/inspection, which in turn can save them time, money, and potential inspection findings.

Regulatory Inspection Readiness
Similar to site audits, this focuses on how to help a site get ready for a regulatory inspection. The QA team provides insight on what to expect, reviews basic documentation, and assists in any other aspects of preparation. Readiness is not something typically discussed proactively. This type of audit can be invaluable to an inexperienced site, averting inspection findings.

SEPTEMBER 22, 2022
DINNER
IN ACCRA AT 7 PM UTC- LOCATION TBC BY THE GHANA DEPARTMENT OF DEFENCE

GHANA2022 Schedule at a Glance

WELCOME GHANA DELEGATION TEAM — DAY 3

Friday, September 23, 2022 at 9 am UTC to 5 pm UTC

on the GHANA ARMED FORCES MILITARY CAMPUS

ITEM	TOPIC	TIME
5.	**Updates from pharma sponsors to discuss the importance of health equality and health equity**	45 min

BREAKFAST WILL BE SERVED AT 6:45 am UTC

(On Tour: Visiting Ghana Hospitals)

Overview of delegation to Accra, Ghana **to operationalize a center of excellence to address health equality and equity for myeloma care on the African continent.**

Operationalizing Clinical Trials in Low-Middle Income Countries (LMIC):

Rationale: There is a need and growing interest to execute clinical trials in LMICs.
The World Medical Association's Declaration of Helsinki was established to guide the ethical conduct of medical research.

The ICH-GCP training (see below) for non-specific protocols in hematology is the first step towards building, strengthening, and collaborating on clinical trials.

The aim is to advance research capacity in Ghana by having a structured effort aimed at facilitating shared learning and knowledge exchange on models for collaboration to increase clinical trials in LMICs.

6.	**Building Trust and Collaboration with Patient Advocacy Organizations**	90 min

The life sciences industry and patient advocacy organizations (PAOs) in cancer care a nd rare disease areas have a shared goal: to improve the lives of those affected by a given disease. Thus, both parties are invested in deepening their understanding of the disease and supporting research that can lead to the development of effective therapies.

Our latest partnerships:

- Patient advocacy communities
- Real-world data use in patient advocacy organizations
- Methods of future-proofing the registry design

LUNCH NETWORKING BREAK

To harness the opportunity presented by African clinical research, we recommend:

- that governments follow the example of countries with well-established clinical research environments through knowledge exchange with more advanced regulators.

The key to harnessing Africa's opportunity is strong commitment by:

- Government, industry, regulatory bodies, and community leaders
- Alongside systematic and sustained concrete actions including investment in expanding clinical research infrastructure (eg, regulatory experts and infrastructure, laboratories, clinical sites) and
- Supply chains for clinical research materials such as reagents and equipment.

Ultimately, transforming Africa into a more accessible, well-regulated trial destination is the most compelling way to persuade industry sponsors not to sacrifice diversity in clinical trials.

- **ICG-GCP Certificate Award Ceremony (ALL)**
- **Next Steps**
- **Summary of follow-up items**
- **Close of Delegation/Meeting**

(continued next page)

WELCOME GHANA DELEGATION TEAM **DAY 3** continued

ITEM	TOPIC	TIME
	SEPTEMBER 23, 2022 **DINNER** **IN ACCRA AT 7 PM UTC- LOCATION TBC BY THE GHANA DEPARTMENT OF DEFENCE**	
	RECAP DELEGATION GOAL: • Operationalize a center of excellence to address health equality and health equity for patient care on the African continent. • Complete Local ICH-GCP Clinical Trials Education • Complete a National Hospital Tour in Ghana to support the pre-screening of potential Ghana clinical trial sites to pre-qualify for a potential proof of concept pilot clinical trial.	
	END OF DAY 3	

GHANA2022 Schedule at a Glance

WELCOME GHANA DELEGATION TEAM **DAY 4**

Saturday, September 24, 2022

on the GHANA ARMED FORCES MILITARY CAMPUS

ITEM	TOPIC	TIME
	BREAKFAST MEETING POST-DELEGATION DEBRIEF MEETING	10 min
8.	**Debrief/Follow-Up/Call to Action**	
	CLOSE DELEGATION	
	AIRPORT TRANSFERS	

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Registration Information

All members of the delegation should have already contacted Mimi Choon-Quinones to receive their invitation letters from the Ghana Armed Forces and Ghana Ministry of Health to accompany the Visa application. It is common for the Visa Process to take 6-8 weeks.

Hotel details should have already been requested as part of the Visa application. Discounted accommodation was reserved at the Accra Ghana Marriott:

ACCRA GHANA MARRIOTT
Liberation Road, Airport City, Accra, Ghana

https://www.marriott.com/en-us/hotels/accmc-accra-marriott-hotel/overview/?scid=bb1a189a-fec3-4d19-a255-54ba596febe2&y_source=1_NTk3Mjk1My03MTUtbG9jYXRpb24ud2Vic2l0ZQ%3D%3D

MARRIOTT

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022

Meeting Policies/Health and Safety Protocols

Partners for Patients (PFP.NGO) and any delegates traveling with PFP.NGO will comply with applicable national, state, and local mandates and other guidance. Policies for each event will follow The African CDC and public health recommendations, federal, state, and local regulations, and transmission rates applicable at the time of the event.

PFP.NGO may change, update, or add to these requirements at any time to protect the health and safety of delegates and others. Delegates must comply with relevant policies and requirements as communicated by PFP.NGO.

Accra Marriott Hotel Requirements:

The hotel has implemented a variety of protocols and practices in response to the COVID-19 pandemic, including but not limited to social distancing measures, contactless experiences and enhanced cleaning protocols and housekeeping services. Please be respectful of these protocols and of the hotel guests around you.

Guests are required to complete and provide the mandatory FORM C-Ghana Immigration Act 573 prior to check-in. The Form can be found here: https://qrcgcustomers.s3-eu-west-1.amazonaws.com/account8625061/29332681_1.pdf?0.6066487342280995

Government and Health Requirements:

Travelers must show proof of vaccination against yellow fever to enter Ghana. All travelers entering Ghana must complete the Health Declaration Form. The Health Declaration DOES NOT replace a Visa.

It is highly recommended that travelers also consider the following vaccines, if they don't already have them: Measles, Rubella, Typhoid, Polio, Varicella, Mumps, Diphtheria, Influenza, Tetanus, and Pertussis.

*Please see next page for **Covid-19 Policies.**

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Meeting Policies/Health and Safety Protocols

COVID-19 Policies:
Accra Kotoka International Airport is open for regular international passenger travel. All travelers 18 years-old and older arriving in Ghana will be required to provide evidence of full vaccination for a COVID vaccine.

Citizens of Ghana and foreign residents who are not fully vaccinated, will need to provide a negative PCR test result no more than **48 hours** old and will undergo an antigen test upon arrival in Ghana.

- **COVID test before arrival:**
  Unvaccinated travelers must present a negative PCR test taken within **72 hours** before departure. Vaccinated travelers do not need to show a negative COVID test.
- **COVID test on arrival:**
  Unvaccinated travelers must take a mandatory antigen test on arrival. Children aged 5 to 12 will be tested on arrival, free of charge. Vaccinated travelers do not need to show a negative COVID test.
- **COVID test exemptions:**
  Children under 5 and fully vaccinated travelers.

Quarantine Requirements:
Unvaccinated travelers and travelers who tested positive on arrival will have to quarantine for 7 days.

Please consult your respective embassy for more information.

All delegates, regardless of vaccination status, agree not to attend any events if they have an active case of COVID or if they are experiencing possible symptoms of COVID, unless and until they receive a negative COVID Test.

Delegates will be expected to take common actions to reduce the risk of COVID transmission and to behave responsibly (including leaving the event area) in case of exposure to a COVID case or experiencing symptoms. In such case, attendees should seek appropriate medical attention, including a COVID test, and must immediately inform PFP.NGO should a COVID test be positive during the event or in the 14 days following the event.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Mimi Choon-Quinones,
PFP Founder, Chairman, Board Of Trustees,
PhD, MBA, LLM'21

Mimi is the Chairman, Board of Trustees at Partners for Patients NGO (Serving 193 United Nation Countries For Non-Profit). She founded the organization in 1990. Her first partnership over 30 years ago was with The International Lions Club and New York City Schools serving Glaucoma Patients. Over the years, she also worked very closely with The African Enterprise to help educate HIV orphans including supporting a food, medical and orphanage program. Recently, her research included partnering with Sub-Sahara Africa medicinal military leaders to spur policy-shaping to support healthcare infrastructure improvements in Uganda, specifically to find the cure for Burkitts Lymphoma and Blood Cancer.

Mimi has worked in Pharma for +25 years working at Merck, Novartis and Roche.

She is passionate about advocating for patients and caregivers by improving healthcare policies, advancing medical knowledge, driving innovative digital solutions in the quest to increase medical access to treatments for patients, especially in the most marginalized regions of the world.

Daniel Mingle MD, MPH,
Key Opinion Leader Program Manager
Non-Communicable Disease Control Program
Ghana Armed Forces Medical Service

Daniel is a Public Health Physician Specialist with the Ghana Armed Forces. He has experience in the Pharmaceutical and Biotechnology industry where he worked as a Country Medical Manager. He is currently involved in improving cancer disease awareness among personnel, identifying and bridging patient and physician knowledge gaps. He is also involved in identifying hurdles encountered in the oncology disease management space to help improve access to the right standard of care.

Emmanuel Sarkodie MD,
Head of Hematology Department, 37 Military Hospital, Ghana; Commissioned Officer – Ghana Armed Forces, Key Opinion Leader

Lt Cdr Emmanuel Sarkodie is a specialist hematologist and currently the head of the hematology department at the 37 Military Hospital, Accra, Ghana. He has a special interest in multiple myeloma and is currently spearheading improving awareness, early diagnosis, and affordable access to the right to standard of care. He is also a commissioned officer in the Ghana Armed Forces and has served with the United Nations Peacekeeping Force in the Ivory Coast, Mali and Central African Republic.

Asligul Kendirci,
PFP CEO & President Middle East & North Africa,
Ass. Prof. Istinye University, Pharmacy Faculty
Founder - GM of ASCOT Science CRO Key Opinion Leader, PFP Volunteer

Dr. Aslıgül Kendirci is a scholar and business executive in biotechnology, pharmaceutical discovery, and clinical development with strong acumen in product development, including regulatory science. She has over 35 years of experience in the industry and academia collectively. She has successfully contributed to and led the global multi-country development of pharmaceuticals, including, for example, at Roche, Abbott, and Bayer Pharmaceuticals. She is also a visiting lecturer at Istinye University in İstanbul. Dr. Kendirci is an internationally recognized leader in biotechnology and clinical trials, particularly in clinical research regarding oncology and cancer therapeutics innovation, antimicrobials, infectious diseases, and CRO management. She has deep expertise in medical, regulatory, and clinical research in the pharmaceutical and biotechnology sectors in Turkey, the US, the Middle East, and Africa. She has been an active lecturer at Clinical Trials School for 16 years in Turkey, the Middle East, and Africa, where she was instrumental in launching the school. Dr. Kendirci has most recently founded Ascot Science after being a Clinical Development Director at Roche Pharmaceuticals, as Head of Turkey, the Middle East, and Africa.

Dr. Kendirci holds a Ph.D. in Pharmaceutical Technology from the Ege University Pharmacy Faculty and a Diploma from the First International Advanced Course on Technology and Control of Drugs at the Italian Ministry of Health. Additionally, she is a Member of the Board of Trustees at Partners for Patients, a Patient Advocacy Research Organization where she is President and CEO of the Middle East and Africa.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Charles Amidi PMP®,
PFP Chief Clinical Operations Officer, Senior Clinical Trials Manager, Global Lead, Novocure, PFP Volunteer

Charles is a senior clinical trial expert that has gathered 20 years of experience in the pharmaceutical industry, and biotech, across European and American markets. With 14 years of proven track record supporting international clinical study conduction, combined with 6 years of involvement in the commercial department. This double experience was the opportunity to become an accomplished senior clinical trial expert with a broader view on drug development, with a good understanding of market access challenges and their impact on clinical trials. Experienced in oncology, rare disease, cardiology, cosmetology, food supplement and IBD. Multi-lingual with operational command over French and English and basic knowledge over German.

Al O. Pacino,
PFP President Technology, BlueCloud CoFounder & General Manager, PFP Volunteer

A senior executive and with more than 35 years in healthcare and clinical research, Al is an innovator in the industry. He introduced the phenomenon and coined the phrase "trial drift", and along with other experts in the field, brought to the forefront the issues, causes, consequences and solutions associated with such clinical research phenomenon. With his extensive experience with standardization, collaborative networks creation, Al is currently working alongside industry leaders to eliminate redundancies and minimize costs within healthcare and clinical research. Al is a United States Army veteran and a 15-year head and neck cancer survivor.

Sheri Campbell,
PFP Senior Vice President, BlueCloud COO Operations and Implementation, PFP Volunteer

Sheri has more than 35 years of in-depth experience in start-up and implementation of managed care plans, practice management, clinical research and innovative, global networking technology. She enjoys the challenge and privilege of building healthcare and research company start-ups – from business development to implementation, operations and training/education. Sheri is passionate and driven to make a difference in the healthcare and research industries, as well as the lives of others. She lost her father to cancer.

Frank Naus,
PFP Chief Operations Officer, Lumedi, Inc. CEO, PFP Volunteer

Frank Naus is the Chief Executive Officer of Lumedi Inc., a data platform company that supports clinical research, patient support programs, and education/training systems, and is a Partner at Launchit Ventures Inc., a health-tech focused Venture Studio. He is an Instructor in the Clinical Trials Management program at Western University. He started his career in clinical research and sales with Astra Pharma Inc. (AstraZeneca) and ran several clinical research organizations. He spent five years in the public sector as Director of Research Administration and then Vice President, Research at Hamilton Health Sciences Corporation. Frank earned his Doctorate in Business Administration from Walden University and has an MBA from Wilfrid Laurier University and MSc and BSc degrees in Applied Health Sciences from the University of Waterloo.

Christina Sanguinetti,
PFP Chief Medical Communications Officer, Laconic Medical Writing Inc. Founder and President, Otium Regulatory Inc. CoFounder, Medical Writing Course Instructor and Content Developer, Career Mentor, PFP Volunteer

Christina has a Medical Sciences Degree in microbiology and immunology and more than 15 years of clinical research and medical writing experience. She produces medical & scientific content helping pharmaceuticals, health organizations, biotech start-ups, government agencies, not-for profits organizations, NGOs, academic institutions, and research centers meet clinical data reporting and publication requirements. She also teaches medical writing to clinical research professionals and offers mentorship to other writers in the industry.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Paul Keown MD,
PFP Global Advisory Board, Professor of Medicine at the University of British Columbia Key Opinion Leader and Project Advisor

Dr. Paul Keown received his training in medicine, immunobiology and transplantation at the universities of Manchester, Paris and Western Ontario, his research doctorates in medicine and science from the University of Manchester, and his MBA from Simon Fraser University. His research interests focus particularly on the immune response in transplantation and autoimmune disease and extend from molecular genetics to healthcare economics. He is Professor of Medicine at the University of British Columbia and has served as Executive Director of the BC Transplantation Program, Director of Immunology, Head of the Division of Nephrology, President of the Canadian Transplantation Society, Lead, Genome Canada Transplant Consortium, Lead, Cluster of Excellence for Precision Medicine UBC. Member of Council and President of the XXIII International Congress of the Transplantation Society.

Mike Barnett,
Clinical Professor Emeritus at the University of British Columbia, Key Opinion Leader

Dr. Mike Barnett trained in medicine at the University of Nottingham (1972 – 1977) and in medical oncology at St. Bartholomew's Hospital, London (1981 – 1986). He has spent most of his career to date (1986 – 2001 and 2003 – 2020) in Vancouver (at British Columbia Cancer Agency, Vancouver General Hospital, St. Paul's Hospital & University of British Columbia) where he has served as Director of the Leukemia/Bone Marrow Transplant (BMT) Program, Chair of the Leukemia Tumour Group, Head of Hematology and Associate Head of Medicine. He spent two years (2001 – 2003) back in London (at St. Bartholomew's Hospital & Queen Mary University of London) as Professor of Transplantation Oncology and Lead Clinician for Haematological Oncology (2002 – 2003). He retired from the Leukemia/BMT Program and Division of Hematology in 2019. Since then, he has taken on a number of new roles, including member of the Scientific & Research Staff in the Immunology Laboratory at Vancouver General Hospital. He continues to have a particular interest in the development of treatment for patients with blood cancer.

Wim Goettsch,
Government Attendee, Associate Professor of HTA at the WHO, Key Opinion Leader

Dr. Wim Goettsch is an Associate Professor of HTA at the WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Netherlands. He is also currently a Special Advisor HTA at the Dutch National Health Care Institute. He was the Director of the EUnetHTA JA3 (2016-2020) Directorate end the Chair of the EUnetHTA Executive Board between June 2016 and March 2018. He has a PhD in immunotoxicology and an advanced education in (pharmaco)-epidemiology and pharmacoeconomics. He has more than 100 publications in peer-reviewed international journals.

Yvette Venable BA,
Vice President of Patient Engagement

Yvette is ICER's Vice President of Patient Engagement and leads the organization's efforts to strengthen the patient voice across ICER's processes, research and policy reports. Yvette is an accomplished global health care leader, with more than 20 years' experience in patient advocacy, health policy, and biopharma communications. Prior to joining ICER, Yvette led global and European patient access, public affairs and advocacy functions within life sciences companies. Across a range of serious diseases including cancer, hemophilia, and ultra-rare conditions, she championed new ways of making drug development more patient-centric and worked extensively with advocates around the world to help patients drive policy change that elevated standards of care and achieved access to health care. Before entering the biopharma industry, Yvette held increasingly senior roles within three global health policy and communication consultancies.

Originally from the Chicago area, Yvette lived and worked in three different European countries for more than 14 years and is currently based in Boston, Massachusetts. She graduated with honors from Drake University.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Marcell Csanadi,
Health Economist, Syreon Research Institute

Marcell Csanádi, PhD joined Syreon Research Institute in 2013. He received his BSc in Financial management from the Budapest University of Technology and Economics. He completed the Health Policy, Planning and Financing MSc program at Eötvös Loránd University in Budapest in 2014. He received his PhD degree in 2021 at the Doctoral School of Pharmacology and Pharmaceutical Sciences at University of Pécs. His research focused on the evidence base of reimbursement decisions on health technologies in Central and Eastern European countries. At Syreon Research Institute he is mainly working on research projects related to health policy and health care financing. He also works in the department of European Collaborative Research at SRI and was involved into Horizon 2020 projects.

Karlo Martin,
Senior Real World Evidence Partner, PHAGE Corporation

Karlo is a patient advocate and pioneer in bringing access to personalized medicines to global markets. As the senior real-world evidence partner at PHAGE Corporation he works directly with pharmaceutical, medical device, and diagnostic manufacturers in supporting product development. Starting his career in the clinic, Karlo was a cytogeneticist diagnosing constitutional chromosomal abnormalities and neoplastic diseases. Getting a front row seat of pairing someone's genetic profile and seeing how they responded to treatment drove Karlo into industry to learn more about personalized medicine.

His goal is to not only bring innovative treatments to the market but also focus on providing routes of access to desired health outcomes that are patient centric. Ultimately his goal is to champion marginalized patient populations and reduce the access barriers to care.

Dirk Hose,
Professor of Medicine, VUB Brussels,
Key Opinion Leader

Dirk Hose is a member of the IMF Working Group and a professor of medicine in VUB Brussels. He is interested in understanding the pathogenesis of multiple myeloma and corresponding plasma cell disease like AL-amyloidosis including the development of novel therapeutic approaches and conducting of clinical trials.

Tony Blau,
PFP Global Advisory Board, All4Cure, Founder, CEO, PFP Volunteer

Tony Blau founded All4Cure after 27 years as a Professor of Medicine/Hematology and physician-scientist at the University of Washington (UW). His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases. At UW, Tony founded the Center for Cancer Innovation, which brings together a distributed network of investigators to help patients with advanced cancer. Tony co-founded the UW Institute for Stem Cell and Regenerative Medicine and chaired the Molecular and Cellular Hematology Study Section for the National Institutes of Health. He has authored more than 90 scientific publications. Diagnosed himself with myeloma in April 2015, Tony infuses All4Cure with an incredible sense of urgency to improve the prospects for cancer patients now and in the future.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Sibel Blau,
Co-Founder and CEO, Quality Cancer Care Alliance

Dr. Sibel Blau is a Hematologist and Oncologist with special interest and expertise in breast cancer, multiple myeloma and stem cell transplant. She is the Medical Director at Northwest Medical Specialties, PLLC, where she also runs the clinical research and Precision Medicine program. She is one of the founding members and the President/CEO of the Quality Cancer Care Alliance Network (QCCA) that is a national organization with a focus of value-based care, education, and research as well as Exigent Research, an innovative research network of independent practices throughout the US to provide high quality, accelerated and accessible research to the communities where patients are treated. She is a board member and past President of Washington State Medical Oncology Society (WSMOS). She is involved in multiple committees at national organizations like ASCO, COA, ACCC. She is also a member of All4cure, which is a transparent platform for discussion between experts in myeloma, researchers, scientists and patients. She is the founder and president of the Journey Fund which is a community-based, not-for-profit organization committed to cancer patients facing barriers that affect their treatment with donations and community resources that make it possible for us to assist cancer patients facing social, financial, or emotional obstacles, toward a courageous journey, with dignity.

David D'Alessandro,
Economics Expert

Davide D' Alessandro is a Global Portfolio Specialist in Innovation & Development at Abbott. His focus is on drive implementation of EPD's (Established Pharmaceutical Division's) project management strategy and serve as catalyst for improved portfolio delivery / strategy execution. Previously, he has been working as a Global Strategy & Portfolio Planning Manager in Medical Affairs at F.Hoffmann - La Roche, focusing on measuring value for MA activities. He holds a Master of Science in Business Management with major on Strategy Consulting from University of Lausanne. Previously, he had been studying Economics in Rome, Italy and Utrecht, the Netherlands. Davide has a passion for Healthcare and particularly the potential this industry has in delivering tangible value for patients, payers, healthcare providers and societies.

In his free time Davide loves discovering the world with his family. Additionally, he likes track & field running, reading about innovative entrepreneurship, environmental sustainability, Space and Formula 1. He believes in the combination between arts and corporate world.

Kayar Raghavan,
Mentor, Angel Investor & NED

Kayar Raghavan advises invests and mentors startups on due diligence, strategy, value accretion, fundraise,shareholder agreements and investor relations. A serial investor in FinTech, MedTech & all things SmartTech in UK, India & USA and director on several boards and a charity, Raghavan is known for exhibiting great temperament and judgment in challenging situations. A Financial Times qualified Non-Executive Director, Raghavan also places emphasis on Risk Management & Governance in his roles as Advisor and Non- Executive Director.

Raghavan's current portfolio of 50 angel investments includes startups in domains across medical devices, data science/AI, crowdfunding platform, telecomm services, lending, eCommerce, marketplace, education, solar energy, big data and fintech. In his earlier avatar, Raghavan was a senior bank executive with Citi, his rich international experience, across continents, of 40 years spanning Banking business, operations and technology. Raghavan also advised multinational CEOs and performed due diligence for a multi-billion dollar private equity deal in his advisory and consultancy role in the later years of his formal career.

Raghavan takes pleasure in occasional freelancing in financial journalism and investing. His interests include, in addition to the Startup world, politics, economics, finance and speaking at seminars and conferences. A graduate of Loyola College, Madras, India, Raghavan also did a Masters course in Management, sponsored by his then employer, Citibank, at George Washington University, USA. Raghavan speaks several Indian languages and a dash of French.

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Caroline Pecquet MBA,
Executive Communication Expert. IMF Volunteer and Advisor specific to this meeting

Caroline Pecquet is a global corporate communications professional with a 20-year career in the USA and Europe, having worked in a number of industries, including the pharmaceutical and biotechnology sectors. She has experience in a variety of communications disciplines, including executive and internal communications, media relations and stakeholder engagement, among others. Caroline was the Head of Communications for Hoffman-La Roche's Pharma region of Eastern Europe, Middle East and Africa, as well as the Head of Communications for the Pharma Global Technical Operations function of the same company, and has held roles with AstraZeneca and Genentech. She also led and implemented communications strategies for various corporate and government clients in her roles with a global communications consulting firm. Caroline has an undergraduate degree from Georgetown University and an MBA from New York University's Stern School of Business.

Ricardo Lopez-Barquilla,
Co-Founder, All4Cure

Ricardo Lopez-Barquilla is a co-founder and technology advisor at All4Cure. He is the VP of Devices Quality at Microsoft and was part of the original team that started and currently develops the Microsoft Surface devices. Especially comfortable navigating the boundary areas between hardware and software, he has a track record of success in building first versions of new products. Ricardo has a PhD in Telecommunications from the Polytechnic University in Madrid.

Renahan Gil,
to come

To come

Nadir Ammour,
Member of the Executive Committee of the EHR4CR champion project, and a member of the i-HD (Institute for Innovation through Health Data) Research Team Member

To come

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Teresa Regueiro,
to come

To come

Rouwayda Dana,
IMC Clinic, Key Opinion Leader

To come

Vibhor Gupta,
Founder of Pangaea Data, Key Opinion Leader

To come

Lenka Kellermann,
Founder and President of Oncology Information Services in Germany. IMF Volunteer & Advisor specific to this meeting

To come

Peter M. Wehmeier,
MD

To come

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022
Core and extended team bios

Euginia (Gina) Nicoletti,
PFP Global Head in Health Science Education, Holy Name of Mary College School-Dept of Science- Medical Science Leader, PFP Volunteer

Experienced Science and Education Specialist with a demonstrated history of working in the pharmaceutical and secondary education industries. Skilled in Quality Management, Pharmaceutical Chemistry (including Sterile Drug Manufacturing) and Quality Control, Good Manufacturing Practices (cGMPs), Secondary Education; Chemistry, Biology & Biotechnology, Change Control, and Lesson Planning. A certified Joint Health and Safety Committee member. Strong research professional with a Master of Science in Administration, a Master of Education (MEd) in Science/Chemistry/Biology. Completed Ontario Principal Qualification Program – Parts 1 & 2 and Special Education – Part 1, 2 & Specialist. Completed E-Learning teaching qualifications.

Sébastien Wischlen,
CEO, CancerDataNet GmbH

To come

PARTNERS FOR PATIENTS
SINCE 1990

GHANA2022

Sponsors

The Project C.A.R.E initiative has been completely self-funded by Partners for Patients. If you would like to donate or be part of the PFP project, please contact Project founder Dr. Mimi Choon-Quinones at info@pfp.ngo